Who founded ImmunoVec?

ImmunoVec was founded by Dillon Woodward in 2019.

Who are ImmunoVec's investors?

ImmunoVec's investors include Ying Fund.

How much funding has ImmunoVec raised?

ImmunoVec has disclosed $17M raised across 2 rounds.

Where is ImmunoVec headquartered?

ImmunoVec is headquartered in Los Angeles, US.

ImmunoVec

Los Angeles, US · Founded 2019 · 12 employees on LinkedIn · 1 known investors

Find your way into ImmunoVec

168 people in our graph share verified history with the ImmunoVec team — schools, employers, funds. One of them is your warm intro.

Damir Becirovicunlockedknows Dillon Woodward · together at University of Southern California (overlapped)

×6knows the team · via University of Southern California

×2knows the team · via ImmunoVec

knows the team · via Surf Air

×2knows the team · via Anthem Venture Management, Llc

ImmunoVec develops programmable DNA-based in vivo medicines that use cell type- and cell state-specific synthetic promoters to control payload expression in targeted cells for treating cancer and autoimmune disease. Its expression cassettes can be incorporated into both viral and non-viral delivery vehicles such as lentivirus, AAV, lipid and polymeric nanoparticles, and exosomes.

Biotech Deep Tech

Founders & leadership

ImmunoVec was founded in 2019 by Dillon Woodward.

Dillon Woodward inDirector of Marketing & Partnerships; Co-FounderJunior Partner / Marketing Director at Anthem Venture Management, Llc

William WoodwardExecutive

Ryan WongNamed on SEC filing

Douglass LorenzenNamed on SEC filing

Board

Chris LucasBoard director

Investors · 1

Ying FundLos Angeles

Reported raises · per SEC filings

Form D private placements

$17M disclosed across 2 rounds · 2021–2026

▶$12.7MraisedJul 2026 · 10 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Ryan WongExecutive Officer, Director
William WoodwardExecutive Officer, Director
Douglass LorenzenExecutive Officer, Director, Promoter
Chris LucasDirector

Offering amount: $15M
Amount sold: $12.7M
First sale: Jun 2026
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$4.3MraisedMar 2022 · 25 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Dillon WoodwardDirector
William WoodwardExecutive Officer, Director, Promoter

Offering amount: $4.3M
Amount sold: $4.3M
First sale: Nov 2021
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does ImmunoVec do?: ImmunoVec develops programmable DNA-based in vivo medicines that use cell type- and cell state-specific synthetic promoters to control payload expression in targeted cells for treating cancer and autoimmune disease. Its expression cassettes can be incorporated into both viral and non-viral delivery vehicles such as lentivirus, AAV, lipid and polymeric nanoparticles, and exosomes.
Who founded ImmunoVec?: ImmunoVec was founded by Dillon Woodward in 2019.
Who are ImmunoVec's investors?: ImmunoVec's investors include Ying Fund.
How much funding has ImmunoVec raised?: ImmunoVec has disclosed $17M raised across 2 rounds.
Where is ImmunoVec headquartered?: ImmunoVec is headquartered in Los Angeles, US.